The Cyclin Dependent Kinase 6 pipeline drugs market research report outlays comprehensive information on the Cyclin Dependent Kinase 6 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Cyclin Dependent Kinase 6 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Toxicology, Infectious Disease, and Genetic Disorders which include the indications Solid Tumor, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Chemotherapy Induced Myelosuppression, Chemotherapy-Induced Diarrhea (CID), Human Immunodeficiency Virus (HIV) Infections (AIDS), Epstein–Barr Virus (HHV-4) Infections, and Neurofibromatoses Type I (Von Recklinghausen’s Disease). It also reviews key players involved in Cyclin Dependent Kinase 6 targeted therapeutics development with respective active and dormant or discontinued products.
The Cyclin Dependent Kinase 6 pipeline targets constitutes close to 57 molecules. Out of which, approximately 56 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 4, 9, 6, 7, 6, 16, and 8 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Cyclin Dependent Kinase 6 overview
Cell division protein kinase 6 (CDK6) is an enzyme encoded by the CDK6 gene. It is involved in initiation and maintenance of cell cycle exit during cell differentiation, prevents cell proliferation and regulates negatively cell differentiation. It is required during thymocyte development. It promotes the production of newborn neurons, probably by modulating G1 length, changes in the actin cytoskeleton including loss of stress fibers, and enhanced motility during cell differentiation. It prevents myeloid differentiation by interfering with RUNX1 and reducing its transcription transactivation-activity.
For a complete picture of Cyclin Dependent Kinase 6’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
